Agios Pharmaceuticals, Inc.
Cambridge
Massachusetts
United States
344 articles about Agios Pharmaceuticals, Inc.
-
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
1/26/2021
– 37 Percent of Patients Treated with Mitapivat Achieved ≥33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) – – 22 Percent of Patients Treated with Mitapivat Were Transfusion-Free During the 24-Week Fixed Dose Period – – Safety Profile Consistent with Previously Reported Data
-
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
1/17/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, reported a full analysis of the final data, including mature overall survival results, from its global Phase 3 ClarIDHy trial of TIBSOVO® in patients with previously treated isocitrate dehydrogenase 1 mutated cholangiocarcinoma.
-
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
1/11/2021
Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021
-
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
1/5/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, announced that the company is scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. ET.
-
Servier to Acquire Agios Pharmaceuticals' Oncology Business
12/21/2020
- Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 Billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug discovery capabilities
-
The company bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios in a deal worth up to $2 billion.
-
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
12/21/2020
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier,
-
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
-
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
-
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
12/7/2020
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported updated data from a Phase 1 trial of mitapivat, the company’s first-in-class pyruvate kinase R (PKR) activator, in patients with sickle cell disease.
-
Topline results from Agios Pharmaceuticals’ Phase III ACTIVATE trial show that treatment with mitapivat was associated with a significantly greater hemoglobin response compared with placebo in patients with pyruvate kinase deficiency.
-
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
12/1/2020
– 40 Percent of Patients Treated with Mitapivat Achieved a Sustained Hemoglobin Increase of ≥1.5 g/dL Compared to 0 Placebo Patients (p <0. 0001 ) – – Safety Profile Consistent with Previously Reported Data – – Topline Data from the Mitapivat Phase 3 ACTIVATE -T Trial in Regularly Transfused PK Deficiency Expected in Q1 2021 –
-
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
11/30/2020
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the launch of Anemia ID, a program providing no-cost genetic testing for patients with suspected hereditary anemias
-
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
11/25/2020
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 2:00 p.m. ET.
-
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
11/12/2020
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients with sickle cell disease. Mitapivat is an investigational, oral, small molecule allosteric activator of wil
-
Agios Reports Business Highlights and Third Quarter 2020 Financial Results
11/5/2020
Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million
-
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual MeetingCompany to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET
11/4/2020
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that a broad set of clinical and translational data from its oncology and rare genetic diseases programs will be presented at the American Society of Hematology (ASH) Annual Meeting being held virtually December 5–8, 2020. In total, eight abstracts led by Agios will be presented, as well as three
-
Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020
10/29/2020
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a webinar focused on its pyruvate kinase-R (PKR) activation clinical programs and the commercial outlook across three distinct hemolytic anemias on Thursday, November 19, 2020 from 8:00 a.m. to 10:30 a.m. ET.
-
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020
10/22/2020
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company will host a conference call and live webcast on Thursday, November 5, 2020 at 8:00 a.m. ET to report its third quarter 2020 financial results and other business highlights.
-
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
10/16/2020
– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –